1,3-dipropyl-8-cyclopentylxanthine has been researched along with Cystic Fibrosis of Pancreas in 13 studies
DPCPX : An oxopurine that is 7H-xanthine substituted at positions 1 and 3 by propyl groups and at position 8 by a cyclohexyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Efficacy was determined using nasal transepithelial potential difference and sweat chloride measurements prior to dosing and at 1, 2, and 4 hr postdose." | 2.70 | A phase I randomized, multicenter trial of CPX in adult subjects with mild cystic fibrosis. ( Ahrens, RC; Aitken, ML; Hilliard, KA; Kelley, TJ; Konstan, MW; Launspach, J; McCarty, NA; Milgram, LJ; Regelmann, WE; Standaert, TA; Teresi, M; Tuthill, C; Weatherly, MR, 2002) |
| "Cystic fibrosis is an autosomal recessive disorder affecting chloride transport in pancreas, lung, and other tissues, which is caused by mutations in the cystic fibrosis transmembrane regulator (CFTR)." | 1.29 | A1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine selectively activates chloride efflux from human epithelial and mouse fibroblast cell lines expressing the cystic fibrosis transmembrane regulator delta F508 mutation. ( Barnoy, S; Cabantchik, ZI; Eidelman, O; Guay-Broder, C; Guggino, WB; Jacobson, KA; Pollard, HB; Turner, RJ; Vergara, L; Zeitlin, PL, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (61.54) | 18.2507 |
| 2000's | 4 (30.77) | 29.6817 |
| 2010's | 1 (7.69) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chung, WJ | 1 |
| Goeckeler-Fried, JL | 1 |
| Havasi, V | 1 |
| Chiang, A | 1 |
| Rowe, SM | 1 |
| Plyler, ZE | 1 |
| Hong, JS | 1 |
| Mazur, M | 1 |
| Piazza, GA | 1 |
| Keeton, AB | 1 |
| White, EL | 1 |
| Rasmussen, L | 1 |
| Weissman, AM | 1 |
| Denny, RA | 1 |
| Brodsky, JL | 1 |
| Sorscher, EJ | 1 |
| Guay-Broder, C | 3 |
| Jacobson, KA | 4 |
| Barnoy, S | 1 |
| Cabantchik, ZI | 2 |
| Guggino, WB | 1 |
| Zeitlin, PL | 1 |
| Turner, RJ | 3 |
| Vergara, L | 1 |
| Eidelman, O | 5 |
| Pollard, HB | 6 |
| Casavola, V | 1 |
| Rugolo, M | 1 |
| Mastrocola, T | 1 |
| Whörle, C | 1 |
| Rasola, A | 1 |
| Gruenert, DC | 1 |
| Romeo, G | 1 |
| Galietta, LJ | 1 |
| Arispe, N | 1 |
| Ma, J | 1 |
| Kunzelmann, K | 1 |
| Briel, M | 1 |
| Schreiber, R | 1 |
| Ricken, S | 1 |
| Nitschke, R | 1 |
| Greger, R | 1 |
| Al-Nakkash, L | 1 |
| Hwang, TC | 1 |
| Srivastava, M | 2 |
| Andersson, C | 1 |
| Roomans, GM | 1 |
| Zhang, J | 1 |
| Leighton, X | 1 |
| Murtie, J | 1 |
| Jozwik, C | 1 |
| Jacobson, K | 1 |
| Weinstein, DL | 1 |
| Metcalf, EL | 1 |
| McCarty, NA | 2 |
| Standaert, TA | 2 |
| Teresi, M | 1 |
| Tuthill, C | 1 |
| Launspach, J | 2 |
| Kelley, TJ | 2 |
| Milgram, LJ | 2 |
| Hilliard, KA | 2 |
| Regelmann, WE | 1 |
| Weatherly, MR | 2 |
| Aitken, ML | 2 |
| Konstan, MW | 2 |
| Ahrens, RC | 2 |
| Han, SH | 1 |
| Teresi, ME | 1 |
| van Galen, PJ | 1 |
| Fox, C | 1 |
1 trial available for 1,3-dipropyl-8-cyclopentylxanthine and Cystic Fibrosis of Pancreas
| Article | Year |
|---|---|
A phase I randomized, multicenter trial of CPX in adult subjects with mild cystic fibrosis.
Topics: Adolescent; Adult; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; | 2002 |
12 other studies available for 1,3-dipropyl-8-cyclopentylxanthine and Cystic Fibrosis of Pancreas
| Article | Year |
|---|---|
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regu | 2016 |
A1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine selectively activates chloride efflux from human epithelial and mouse fibroblast cell lines expressing the cystic fibrosis transmembrane regulator delta F508 mutation.
Topics: Animals; Cell Line; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; | 1995 |
CPX, a selective A1-adenosine-receptor antagonist, regulates intracellular pH in cystic fibrosis cells.
Topics: Calcium; Cell Line; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Humans; Hy | 1995 |
ATP and A1 adenosine receptor agonists mobilize intracellular calcium and activate K+ and Cl- currents in normal and cystic fibrosis airway epithelial cells.
Topics: 2-Chloroadenosine; Adenosine Triphosphate; Adult; Calcium; Cells, Cultured; Chloride Channels; Cysti | 1993 |
Direct activation of cystic fibrosis transmembrane conductance regulator channels by 8-cyclopentyl-1,3-dipropylxanthine (CPX) and 1,3-diallyl-8-cyclohexylxanthine (DAX).
Topics: Cell Line; Chloride Channels; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; | 1998 |
No evidence for direct activation of the cystic fibrosis transmembrane conductance regulator by 8-cyclopentyl-1,3-dipropylxanthine.
Topics: Animals; Cell Line; Cells, Cultured; Chlorides; CHO Cells; Cricetinae; Cystic Fibrosis; Cystic Fibro | 1998 |
Activation of wild-type and deltaF508-CFTR by phosphodiesterase inhibitors through cAMP-dependent and -independent mechanisms.
Topics: 1-Methyl-3-isobutylxanthine; 3T3 Cells; Animals; Cell Line; Colforsin; Cyclic AMP; Cystic Fibrosis; | 1999 |
Pharmacogenomics of the cystic fibrosis transmembrane conductance regulator (CFTR) and the cystic fibrosis drug CPX using genome microarray analysis.
Topics: Cell Line; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; DNA, Complementary; | 1999 |
Activation of deltaF508 CFTR in a cystic fibrosis respiratory epithelial cell line by 4-phenylbutyrate, genistein and CPX.
Topics: Cell Line; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Epithelial Cells; G | 2000 |
Control of the proinflammatory state in cystic fibrosis lung epithelial cells by genes from the TNF-alphaR/NFkappaB pathway.
Topics: Algorithms; Cell Line; Child; Cluster Analysis; Cystic Fibrosis; Cystic Fibrosis Transmembrane Condu | 2001 |
Use of nasal potential difference and sweat chloride as outcome measures in multicenter clinical trials in subjects with cystic fibrosis.
Topics: Adolescent; Adult; Analysis of Variance; Chlorides; Clinical Trials, Phase I as Topic; Cystic Fibros | 2002 |
A1 adenosine-receptor antagonists activate chloride efflux from cystic fibrosis cells.
Topics: 2-Chloroadenosine; Adenocarcinoma; Adenosine; Cell Line; Chlorides; Chromosome Deletion; Colonic Neo | 1992 |